Sopharma AD-Sofia (FRA:3JR) Debt-to-EBITDA : 2.30 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sopharma AD-Sofia Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sopharma AD-Sofia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €111.0 Mil. Sopharma AD-Sofia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €56.1 Mil. Sopharma AD-Sofia's annualized EBITDA for the quarter that ended in Dec. 2023 was €72.7 Mil. Sopharma AD-Sofia's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.30.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sopharma AD-Sofia's Debt-to-EBITDA or its related term are showing as below:

FRA:3JR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.82 Med: 2.79 Max: 4.3
Current: 1.93

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sopharma AD-Sofia was 4.30. The lowest was 1.82. And the median was 2.79.

FRA:3JR's Debt-to-EBITDA is ranked worse than
50.67% of 75 companies
in the Medical Distribution industry
Industry Median: 1.93 vs FRA:3JR: 1.93

Sopharma AD-Sofia Debt-to-EBITDA Historical Data

The historical data trend for Sopharma AD-Sofia's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia Debt-to-EBITDA Chart

Sopharma AD-Sofia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

2.67

4.30

2.00

1.82

1.87

Sopharma AD-Sofia Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															3.05	1.35	1.52	2.77	2.30

Competitive Comparison of Sopharma AD-Sofia's Debt-to-EBITDA

For the Medical Distribution subindustry, Sopharma AD-Sofia's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma AD-Sofia's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sopharma AD-Sofia's Debt-to-EBITDA falls into.

Sopharma AD-Sofia Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sopharma AD-Sofia's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(110.959	+	56.071)	/	89.4
	=	1.87

Sopharma AD-Sofia's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(110.959	+	56.071)	/	72.676
	=	2.30

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Sopharma AD-Sofia (FRA:3JR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sopharma AD-Sofia Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sopharma AD-Sofia (FRA:3JR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (FRA:3JR) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SPH:Poland SFA:Bulgaria

Address

5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756

Website

https://www.sopharmagroup.com

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are organized based on the production of finished products which include Tablet dosage forms, Ampoule dosage forms, Medical products, Other forms, and Other revenue. Geographically company operates in Bulgaria and internationally.

Sopharma AD-Sofia (FRA:3JR) Headlines

No Headlines